SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, LNSR, ICAD on Behalf of Shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2025
0mins
Source: PRnewswire
Investigation of Companies: Halper Sadeh LLC is investigating Titan Pharmaceuticals, LENSAR, and iCAD for potential violations of federal securities laws and breaches of fiduciary duties related to their recent mergers and sales.
Legal Support for Shareholders: The firm offers legal assistance to shareholders of these companies at no upfront cost, aiming to secure increased compensation or additional disclosures regarding the transactions.
Analyst Views on LNSR
About LNSR
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
